PRFX — PainReform Income Statement
0.000.00%
Last trade - 00:00
- $2.17m
- -$5.85m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 0.689 | 1.67 | 7.21 | 8.87 | 9.58 |
Operating Profit | -0.689 | -1.67 | -7.21 | -8.87 | -9.58 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.28 | -3.83 | -7.24 | -8.78 | -9.34 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.28 | -4.05 | -7.25 | -8.79 | -9.34 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.28 | -4.05 | -7.25 | -8.79 | -9.34 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.41 | -4.05 | -7.25 | -8.79 | -9.34 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.7 | -4.63 | -7.38 | -8.25 | -7.14 |
Dividends per Share |